![[Visit Client Website]](images/banner.gif)
We performed a secondary analysis of North Shore University Hospital's (NSUH) Center for International Blood and Marrow Transplant Research (CIBMTR) data to describe the relapse and survival of our diffuse large cell lymphoma patients in second remission / response undergoing high dose chemotherapy and autologous stem cell transplantation from December 2007 to March 2012.
Our primary aim was to evaluate overall and progression-free survival at 100 days and 1 year post transplant. Descriptive statistics (mean, standard deviation, frequencies and proportions) were calculated for demographics and clinical factors. The Kaplan-Meier product-limit method was used to estimate OS and PFS. Subjects in which the outcomes of interest (death or progression) were not observed were considered censored using their last date of follow-up.
This analysis consisted of 29 patients; mean age 57.85 years. The 100-day and one year overall survival rates were 89.66% and 67.81%, respectively. The 100-day and one year progression free survival rates were 78.57% and 73.33%, respectively. Among those patients who died, the primary causes of death were bacterial infection, recurrence of primary disease, and cardiac failure.
These outcomes appear comparable to those provided by the Center for International Blood and Marrow Transplant Research. Thus allowing us to conclude that Augmented CBV is a viable preparative regimen for patients with relapsed diffuse large cell lymphoma undergoing autologous stem cell transplantation.